Study S002155

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial Evaluating the Safety, Efficacy, and Pharmacokinetic Characteristics of TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

ClinicalTrials.gov record

Registration

Registration: NCT06726577
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 60
Start: 2026-06-04
Primary completion: 2027-01
Lead sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Conditions: Amyotrophic Lateral Sclerosis
Interventions: DRUG:TP04HN106; DRUG:Saline
Results posted: FALSE

Registered primary outcomes

Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R) [Baseline, 10th week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.